SUN PHARMA

sunpharma.com

Sun Pharma is the world's fourth largest specialty generic pharmaceutical company and India's top pharmaceutical company. A vertically integrated business, economies of scale and an extremely skilled team enable us to deliver quality products in a timely manner at affordable prices. It provides high-quality, affordable medicines trusted by customers and patients in over 150 countries across the world. Sun Pharma's global presence is supported by 50 manufacturing facilities spread across 5 continents, R&D centres across the globe and a multi-cultural workforce comprising over 50 nationalities. Sun Pharma fosters excellence through innovation supported by strong R&D capabilities comprising about 2,000 scientists and R&D investments of over 7% of annual revenues.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

SUN PHARMA & ICGEB ANNOUNCE NEW EXCLUSIVE COLLABORATION TO DEVELOP NOVEL DENGUE VACCINE FOR INDIA & GLOBAL MARKETS

SUN PHARMA | October 19, 2016

news image

International Centre for Genetic Engineering and Biotechnology (ICGEB) and Sun Pharma (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, Sun Pharmaceutical Industries Ltd and includes its subsidiaries or associate companies) today announced their new collaboration for development of a dengue vaccine, targeted against all the four serotypes of Dengue virus that cause disease in humans....

Read More

SUN PHARMA FOCUSES ON DERMATOLOGY AS ADDITIONAL ENGINE OF GROWTH FOR GLOBAL CONSUMER HEALTHCARE (GCH) BUSINESS

SUN PHARMA | June 08, 2016

news image

As part of its plans to grow the Global Consumer Healthcare business, Sun Pharma will focus on Dermatology as the fourth engine of growth for its OTC business. As part of this growth strategy, the company today announced roll-out of its first dermatology product through the Global Consumer Healthcare business. Branded as Suncros, this is a sunscreen product, offering maximum protection from harmful UV rays till the inner layers of the skin....

Read More

US FDA RAISES FRESH CONCERNS ON SUN PHARMA'S HALOL PLANT

Pharmaceutical | December 08, 2016

news image

The US Food and Drugs Administration (USFDA) has found deviations in goods manufacturing practices at Sun Pharmaceutical’s Halol plant — a development which might delay revival of the drug maker’s US business. The Halol plant is a key manufacturing unit for Sun Pharmaceutical, which earns about half its revenue from the US market. Halol contributed in high single digits to the company’s US sales till it was served a warning letter in December 2015. The resolution of quality issues at the plant i...

Read More

SUN PHARMA INTRODUCES OPHTHALMIC ANTI-INFLAMMATORY DRUG, BROMSITE IN US MARKET

Sun Pharma | November 29, 2016

news image

Sun Pharma, the world's fifth largest specialty generic pharmaceutical company, has announced the launch of BromSite (bromfenac ophthalmic solution) 0.075% in the US market. A nonsteroidal anti-inflammatory drug (NSAID) indicated for the treatment of postoperative inflammation and prevention of ocular pain in patients undergoing cataract surgery, BromSite will be marketed by Sun Ophthalmics, the company’s branded ophthalmic business division. BromSite is the first branded product launched by the...

Read More
news image

SUN PHARMA & ICGEB ANNOUNCE NEW EXCLUSIVE COLLABORATION TO DEVELOP NOVEL DENGUE VACCINE FOR INDIA & GLOBAL MARKETS

SUN PHARMA | October 19, 2016

International Centre for Genetic Engineering and Biotechnology (ICGEB) and Sun Pharma (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, Sun Pharmaceutical Industries Ltd and includes its subsidiaries or associate companies) today announced their new collaboration for development of a dengue vaccine, targeted against all the four serotypes of Dengue virus that cause disease in humans....

Read More
news image

SUN PHARMA FOCUSES ON DERMATOLOGY AS ADDITIONAL ENGINE OF GROWTH FOR GLOBAL CONSUMER HEALTHCARE (GCH) BUSINESS

SUN PHARMA | June 08, 2016

As part of its plans to grow the Global Consumer Healthcare business, Sun Pharma will focus on Dermatology as the fourth engine of growth for its OTC business. As part of this growth strategy, the company today announced roll-out of its first dermatology product through the Global Consumer Healthcare business. Branded as Suncros, this is a sunscreen product, offering maximum protection from harmful UV rays till the inner layers of the skin....

Read More
news image

US FDA RAISES FRESH CONCERNS ON SUN PHARMA'S HALOL PLANT

Pharmaceutical | December 08, 2016

The US Food and Drugs Administration (USFDA) has found deviations in goods manufacturing practices at Sun Pharmaceutical’s Halol plant — a development which might delay revival of the drug maker’s US business. The Halol plant is a key manufacturing unit for Sun Pharmaceutical, which earns about half its revenue from the US market. Halol contributed in high single digits to the company’s US sales till it was served a warning letter in December 2015. The resolution of quality issues at the plant i...

Read More
news image

SUN PHARMA INTRODUCES OPHTHALMIC ANTI-INFLAMMATORY DRUG, BROMSITE IN US MARKET

Sun Pharma | November 29, 2016

Sun Pharma, the world's fifth largest specialty generic pharmaceutical company, has announced the launch of BromSite (bromfenac ophthalmic solution) 0.075% in the US market. A nonsteroidal anti-inflammatory drug (NSAID) indicated for the treatment of postoperative inflammation and prevention of ocular pain in patients undergoing cataract surgery, BromSite will be marketed by Sun Ophthalmics, the company’s branded ophthalmic business division. BromSite is the first branded product launched by the...

Read More